You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.
Research is accumulating for the improved performance of epigenetic signals over mutations, with multiple commercial efforts well underway.
CNBC reports on firms pursuing blood tests to detect early-stage cancer.
The firm plans to raise as much as $250 million, according to the document filed with the US Securities and Exchange Commission.
Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.
The company reported that its genome-wide methylation approach could detect 77 percent of stage II cancers in its ongoing case-control CCGA study.
During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.
National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.
Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.
In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.